MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
PSNL stock logo

PSNL

Personalis, Inc.

$10.2
0.45
 (4.63%)
Exchange:  NASDAQ
Market Cap:  905.902M
Shares Outstanding:  21.755M
Delayed data
Calculate PSNL Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Diagnostics & Research
   
CEO:  Christopher Hall
Full Time Employees:  228
Address: 
1330 O’Brien Drive
Fremont
CA
94025
US
Website:  https://www.personalis.com
Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples. This platform encompasses several specialized solutions: ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for plasma analysis; NeXT Personal, a specific liquid biopsy designed for individual patient tumor tracking; the NeXT Dx Test, a genomic cancer profiling tool that identifies composite biomarkers for treatment guidance; and the sophisticated NeXT SHERPA and NeXT NEOPS for predicting neoantigens. Additionally, Personalis offers the ACE platform, utilized for diverse clinical and therapeutic applications like neoantigen prediction, biomarker identification, and the selection of new drug targets. Their clientele includes biopharmaceutical companies, academic institutions, non-profit organizations, and government entities. The company has established significant partnerships with organizations such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center. Personalis, Inc. was founded in 2011 and is based in Menlo Park, California.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/05/07 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue73,48184,6140
Gross Profit18,20826,825-53,871
EBITDA-96,807-70,301-70,998
Operating Income-109,936-68,267-88,057
Net Income-108,296-81,284-81,270

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets225,099270,268334,164
Total Liabilities95,65867,31172,979
Total Stockholders Equity129,441202,957261,185
Total Debt48,96244,24731,866
Cash and Cash Equivalents56,98491,415124,245

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-56,258-45,150-74,946
Capital Expenditure-10,911-1,603-4,504
Free Cash Flow-67,169-46,753-79,450
Net Income-108,296-81,284-81,270
Net Change in Cash-32,14434,43132,830

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)218,394.929Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)233,283.733Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)227,400Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)-117,626.989Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)-110,119.713Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)-114,660.276Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)-43,353.896Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)-39,783.386Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)-41,943.004Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)164,403.872Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)175,611.902Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)171,182.731Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)-0.470Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)-0.450Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)-0.490Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)3Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)2Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
84.614M  ?P/S
 (TTM)
: 
14.8
?Net Income
 (TTM)
: 
-81284000  ?P/E
 (TTM)
: 
-11.72
?Enterprise Value
 (TTM)
: 
912.076M  ?EV/FCF
 (TTM)
: 
-10.77
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
-0.44  ?ROIC
 (TTM)
: 
-0.36
?Net Debt
 (TTM)
: 
-140659000  ?Debt/Equity
 (TTM)
: 
0.12
?P/B
 (TTM)
: 
4.4  ?Current Ratio
 (TTM)
: 
6.61

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
N/AFull AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about PSNL valuation

Is Personalis, Inc. (PSNL) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Personalis, Inc. (PSNL) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is PSNL a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether PSNL trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is PSNL’s P/E ratio?

You can see PSNL’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for PSNL?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is PSNL a good long-term investment?

Whether PSNL fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

PSNL

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

4.63
MARKETSnap

Trading Metrics:

Open: 9.56   Previous Close: 9.75
Day Low: 9.48   Day High: 10.3
Year Low: 3.84   Year High: 12.53
Price Avg 50: 7.22   Price Avg 200: 7.86
Volume: 470015   Average Volume: 2.112M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
Could not create stock discussion for PSNL

Relevant news

Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits
09-06-2026 06:00
Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits
Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026
02-06-2026 06:00
Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026
Personalis: Initiating Coverage Of Cancer Testing Biotech With A Buy Rating
28-05-2026 17:14
Personalis: Initiating Coverage Of Cancer Testing Biotech With A Buy Rating
US Agency Broadens Coverage Of Personalis Breast Cancer Test
20-05-2026 14:22
US Agency Broadens Coverage Of Personalis Breast Cancer Test
Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring
20-05-2026 06:00
Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring
Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors
13-05-2026 06:00
Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read